It is with great interest that we read the recent publication by Mazurier[1] regarding the composition, quality control, and labeling of plasma-derived products for the treatment of von Willebrand disease (vWD). We agree that an optimal selection of the product to use in this complicated clinical setting must, among other requirements, be based on the level of safety in eliminating potential blood-born pathogens, and that such information should be made available for all products with the potential to be used in a vWD indication. Mazurier has compared characteristics of the only two products developed for this very special indication, namely Wilfactine® (Laboratoire français du Fractionnement et des Biotechnologies [LFB]; Les Ulis, France) and Wilate® (Octapharma Pharmazeutika Produktionsges. Vienna, Austria; also indicated for hemophilia A), with several other concentrates currently used to treat vWD patients.